Related Experiment Video

Updated: May 25, 2026

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
12:37

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

Published on: February 9, 2016

Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity

Dennis Ladage1, Robert H G Schwinger, Klara Brixius

  • 1Department of Molecular and Cellular Sport Medicine, Institute of Cardiology and Sport Medicine, German Sport University Cologne, Cologne, Germany.

Cardiovascular Therapeutics
|January 28, 2012
PubMed

Insights

Beta-blockers are vital cardiovascular drugs, but tolerability issues persist. Newer generations offer improved side effect profiles and additional benefits like vasodilation, enhancing their therapeutic potential.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Beta-blockers have been mainstays in cardiovascular medicine for 40 years, reducing morbidity and mortality.
  • They are used in conditions like heart failure, post-myocardial infarction, and arrhythmias, but not typically as first-line hypertension treatment, especially in the elderly.

Purpose of the Study:

  • To review the evolving role and benefits of beta-blockers in cardiovascular medicine.
  • To highlight advancements in beta-blocker generations and their improved tolerability and additional therapeutic advantages.

Main Methods:

  • Literature review of beta-blocker usage in cardiovascular medicine.
  • Analysis of the evolution from older to third-generation beta-blockers.
  • Examination of clinical benefits and adverse effect profiles.

Main Results:

  • Beta-blockers effectively manage various cardiovascular conditions.
  • Cardioselective and third-generation beta-blockers offer improved tolerability and additional benefits, including vasodilation, improved insulin resistance, and reduced cholesterol.
  • Acute beta-blocker use impairs exercise capacity, while chronic effects remain debated.

Conclusions:

  • Advancements in beta-blocker pharmacology have led to improved patient tolerability and expanded therapeutic applications.
  • Third-generation beta-blockers represent a significant improvement, offering vasodilation and metabolic benefits alongside established cardiovascular protection.

More Related Videos

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

Conducting Maximal and Submaximal Endurance Exercise Testing to Measure Physiological and Biological Responses to Acute Exercise in Humans07:26

Conducting Maximal and Submaximal Endurance Exercise Testing to Measure Physiological and Biological Responses to Acute Exercise in Humans

Published on: October 17, 2018

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...